Avinnash Gorakssakar, Market Expert is of the view that one may remain invested in Glenmark Pharma.
Avinnash Gorakssakar, Market Expert told CNBC-TV18, "As far as Glenmark Pharma is concerned, if the investment horizon is over a period of say next 12-18 months, I am quite sure that Glenmark Pharma would definitely benefit from its new product molecule development."
"In the short term, the volatility in margins as well as the topline especially from the US markets could remain a little bit under pressure. However, if the medium term horizon is there, I think the investor can definitely hold on; there is no need to sell out in panic or hurry.""The numbers would take some time to stabilise, but FY19 should be a lot better compared to last year. So I think within the pharmaceutical space, this could be a good contra bet but provided the horizon is at least 12-18 months odd, "he said.